The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab Promising for Dermatitis Herpetiformis

Rituximab Promising for Dermatitis Herpetiformis

January 6, 2017 • By Marilynn Larkin

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK—Rituximab may be an effective treatment for recalcitrant dermatitis herpetiformis (DH), according to a recent case study.

You Might Also Like
  • Rituximab for Fatigue & Oral Dryness in Primary Sjögren’s Syndrome
  • AAV Remission Study: Does Rituximab or Azathioprine Work Best?
  • Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

“DH is an autoimmune blistering disease which is commonly associated with celiac disease and can present with debilitating pruritic blisters on extensor surfaces,” explained Dr. Ron Feldman of Emory University School of Medicine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The most common treatments are a gluten-free diet along with the addition of dapsone,” he told Reuters Health. “For patients who do not typically respond to these therapies, other immune-suppressing medications have been utilized with mixed results.”

“This is the first successful case of rituximab therapy used for a recalcitrant case of DH,” he said by email. “The patient had resolution of both his pruritus and skin rash. In addition, the levels of both anti-tissue and anti-epidermal transglutaminase antibodies normalized.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Writing in JAMA Dermatology, online December 28, Dr. Feldman and colleagues describe a man in his 80s with a five-year history of worsening DH. He was put on a gluten-free diet along with dapsone 50 mg daily, but his pruritic rash persisted.

Dapsone was discontinued because of worsening anemia. He began treatment with 3 g sulfasalazine daily, but this was discontinued due to gastrointestinal symptoms.

His disease worsened and became debilitating after stopping sulfasalazine, and he was unable to follow the gluten-free diet that was again recommended. He was put on a tapering course of prednisone from 40 mg to 10 mg daily along with azathioprine titrated up to 2.5 mg/kg daily, but his disease continued to worsen over subsequent months.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

He was then treated with rituximab according to the protocol used to treat lymphoma: four weekly infusions of 375 mg/m2.

Thirteen months after treatment, the patient experienced complete resolution of pruritus and other manifestations of DH, as well as normalization of antibodies against both epidermal and tissue transglutaminases.

He went into remission and has remained symptom-free for up to a year and a half thus far.

Dr. Feldman said, “We are excited about this case since rituximab is well tolerated and can potentially provide long lasting remission with removal of pathogenic autoimmune B cells. Although our patient did not have significant gastrointestinal symptoms, we are hopeful that rituximab may provide similar benefits for patients with celiac disease, in which anti-tissue transglutaminase antibodies play a role, although further research will need to be done to confirm this.”

“As we only present a single case, our results of course need to be replicated with a larger group of patients with DH,” concluded Dr. Feldman. “Rituximab has already shown efficacy in the treatment of other autoimmune blistering diseases such as pemphigus and pemphigoid and may have relevance with other B cell mediated diseases in dermatology.”

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: celiac disease, debilitating pruritic blisters, Dermatitis Herpetiformis, rituximab

You Might Also Like:
  • Rituximab for Fatigue & Oral Dryness in Primary Sjögren’s Syndrome
  • AAV Remission Study: Does Rituximab or Azathioprine Work Best?
  • Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.